Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951922 | 0.90 | MAOA (0.53) | MAOAMAOBCYP19A1CYP1A2CYP2D6 | |
| SCHEMBL18041437 | 0.89 | MAOA (0.51) | MAOAMAOBCYP19A1CYP1A2CYP2D6 | |
| SCHEMBL3065864 | 0.85 | KDM4E (0.57) | MAOAMAOBCYP19A1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10160181 | 0.84 | HDAC2 (0.62) | MAOAMAOBALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1231292 | 0.84 | CYP1A2 (0.65) | MAOAMAOBCYP19A1CYP1A2CYP2D6 | |
| SCHEMBL7836747 | 0.83 | MAOA (0.57) | MAOAMAOBALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL5261796 | 0.83 | MTNR1A (0.51) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL2083314 | 0.81 | MAOA (0.46) | MAOAMAOBCYP19A1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16594319 | 0.81 | NOX4 (0.49) | MAOAMAOBCYP19A1ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27811543 | 0.81 | MTNR1A (0.65) | MAOAMAOBCYP19A1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168966-B1 | BICYCLOANILINE DERIVATIVE | MSD KK (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-2888262-A1 | PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2448927-B1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2014-03-12 | — | — | EP | disclosed |
| WO-2014029732-A1 | PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| EP-2448927-A1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001114-A1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| EP-2254860-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2010-12-01 | — | — | EP | disclosed |
| US-20100222574-A1 | CYCLIC ANILINO - PYRIDINOTRIAZINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-02 | — | — | US | disclosed |
| EP-2168966-A1 | BICYCLOANILINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009106351-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2009-09-03 | — | — | WO | disclosed |
| EP-2096105-A1 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor | Laboratorios Almirall, S.A. (ES) | 2009-09-02 | — | — | EP | disclosed |
| EP-1904461-B1 | CYCLIC ANILINO-PYRIDINOTRIAZINES AS GSK-3 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-12 | — | — | EP | disclosed |
| EP-1971582-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1904461-A2 | CYCLIC ANILINOPYRIDINOTRIAZINES AS GSK-3 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007076431-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007003525-A2 | CYCLIC ANILINO-PYRIDINOTRIAZINES AS GSK-3 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-11 | — | — | WO | disclosed |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | SSTR1, SSTR3, NPY1R | MAOA 184/4885MAOB 154/4885CYP19A1 263/4885 |
| US-20100222574-A1 | CYCLIC ANILINO - PYRIDINOTRIAZINES | NR4A1, NR4A2, NR5A2 | MAOA 2525/4885MAOB 2391/4885CYP19A1 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.